Cancer Research and Treatment

Original Articles

Sarcoma

Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study: Xin Liu, Chengcheng Gong, Jieyun Zhang, Wanjing Feng, Yanjing Guo, Youzhou Sang, Chunmeng Wang, Yong Chen, Jian Wang, Lin Yu, Xiaowei Zhang, Zhiguo Luo; Cancer Res Treat. 2023;55(3):1001-1010. Published online March 3, 2023; DOI: https://doi.org/10.4143/crt.2022.894

Abstract PDF Supplementary Material PubReader ePub

Purpose
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal malignancy that occurs primarily in children and adolescents. The clinical and pathological features of IMT in adult patients are not well understood.
Materials and Methods
We retrospectively searched for records of adult patients with IMT at Fudan University Shanghai Cancer Center from 2006 to 2021. Clinicopathological data, treatments, and outcomes were collected and analyzed.
Results
Thirty adult patients with IMT, mostly women (60.0%), were included. The median age of the patients was 38 (21-77). The most common primary site was abdominopelvic region (53.3%), followed by lungs (20.0%). Seven patients had an abdominal epithelioid inflammatory myofibroblast sarcoma (EIMS). The positivity rate of anaplastic lymphoma kinase (ALK) was 81.5% (22/27). Sixteen patients with advanced ALK-positive disease received crizotinib, with an objective response rate (ORR) of 81.3% and a disease control rate of 87.5%. The median progression-free survival was 20.8 months. EIMS was associated with more aggressive behavior; however, the prognosis was similar to that of non-EIMS patients after treatment with an ALK inhibitor. At a median follow-up time of 30 months (95% confidence interval [CI], 13.6 to 46.4), the 5-year overall survival was 77% (95% CI, 66 to 88) in all patients.
Conclusion
Adult IMTs appeared more aggressive, with a higher incidence of recurrence and metastases, and patients with EIMS had more aggressive cases. Treatment with ALK inhibitors resulted in a high ORR and a durable response, which suggested that ALK inhibitors could be used as a first-line treatment option in adult patients with ALK-positive advanced IMT.

Citations

Citations to this article as recorded by

Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
Xiaoyan Si, Shafei Wu, Ruie Feng, Mengzhao Wang, Hanping Wang, Xiaotong Zhang, Li Zhang, Kaifeng Xu
Thoracic Cancer.2025;[Epub] CrossRef
Case report: Intra-abdominal inflammatory myofibroblastic tumor with mucinous features: a case of rapid recurrence and dissemination post-surgery
Xingchen Li, Jie Li, Chunxiao Liang, Qing Zou
Frontiers in Oncology.2025;[Epub] CrossRef
Clinical diagnosis and treatment of abdominal inflammatory myofibroblastic tumors
Qiang Zhang, Zhi-wei Zhang, Jing Fan, Zhuo-Ma Ji, Chun-Yan Wang, Feng Liu
Discover Oncology.2025;[Epub] CrossRef
Therapeutic strategy and prognostic analysis of inflammatory myofibroblastic tumor in the head and neck: a retrospective study
Feng Liu, Yanchao Qin, Zhiwei Zhang, Mengru Li, Bowei Feng, Wei Ding, Shubin Dong
PeerJ.2025; 13: e19315. CrossRef
Inflammatory myofibroblastic tumor of the adrenal gland: A case report
Jiyao Yang, Hongjin Shi, Haifeng Wang, Yidao Liu
Urology Case Reports.2024; 55: 102763. CrossRef
Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations
Francisco Cristóbal Muñoz-Casares, Javier Martín-Broto, Pedro Cascales-Campos, Juan Torres-Melero, Irene López-Rojo, José Gómez-Barbadillo, Luis González-Bayón, Ana Sebio, César Serrano, Sara Carvalhal, Joaquim Abreu de Souza, Alexandre Souza, Guillermo F
Cancers.2024; 16(15): 2646. CrossRef
Thoracic epithelioid inflammatory myofibroblastic sarcoma: a rare and aggressive disease with case report and literature review
Linke Yang, Pei Li, Runze Liu, Baomin Feng, Huiqing Mao, Xiaoyong Tang, Guangjian Yang
Discover Oncology.2024;[Epub] CrossRef
Metastasized inflammatory myofibroblastic tumor of uterine origin
Thomas Bartl, Michael Deavers, Ryan Blair Kieser, Pedro T Ramirez
International Journal of Gynecological Cancer.2024; 34(10): 1643. CrossRef
Epithelioid inflammatory myofibroblastic sarcoma with exceptionally long response to lorlatinib—a case report
Rafał Becht, Kajetan Kiełbowski, Justyna Żychowska, Wojciech Poncyljusz, Aleksandra Łanocha, Katarzyna Kozak, Ewa Gabrysz-Trybek, Paweł Domagała
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Rare giant epithelioid inflammatory myofibroblastic sarcoma of the abdominal cavity in a child: a case report and review of the literature
Jinzhou Li, Haixing Su, Sheng Zhang, Xianyun Chen, Chongzhi Hou, Tao Cheng
Frontiers in Oncology.2024;[Epub] CrossRef
Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment
PAULINA CHMIEL, ALEKSANDRA SłOWIKOWSKA, ŁUKASZ BANASZEK, ANNA SZUMERA-CIEćKIEWICZ, BARTłOMIEJ SZOSTAKOWSKI, MATEUSZ J. SPAłEK, TOMASZ ŚWITAJ, PIOTR RUTKOWSKI, ANNA M. CZARNECKA
Oncology Research.2024; 32(7): 1141. CrossRef

3,994 View
144 Download
9 Web of Science
11 Crossref

Lung Cancer

Inhibition of lncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition: Deyu Li, Qin Tong, Yuane Lian, Zhizhong Chen, Yaru Zhu, Weimei Huang, Yang Wen, Qiongyao Wang, Shumei Liang, Man Li, Jianjing Zheng, Zhenhua Liu, Huanxin Liu, Linlang Guo; Cancer Res Treat. 2021;53(4):1042-1056. Published online March 9, 2021; DOI: https://doi.org/10.4143/crt.2020.1208

Abstract PDF Supplementary Material PubReader ePub

Purpose
Drug resistance is one of the main causes of chemotherapy failure in patients with small cell lung cancer (SCLC), and extensive biological studies into chemotherapy drug resistance are required.
Materials and Methods
In this study, we performed lncRNA microarray, in vitro functional assays, in vivo models and cDNA microarray to evaluate the impact of lncRNA in SCLC chemoresistance.
Results
The results showed that KCNQ1OT1 expression was upregulated in SCLC tissues and was a poor prognostic factor for patients with SCLC. Knockdown of KCNQ1OT1 inhibited cell proliferation, migration, chemoresistance and promoted apoptosis of SCLC cells. Mechanistic investigation showed that KCNQ1OT1 can activate transforming growth factor-β1 mediated epithelial-to-mesenchymal transition in SCLC cells.
Conclusion
Taken together, our study revealed the role of KCNQ1OT1 in the progression and chemoresistance of SCLC, and suggested KCNQ1OT1 as a potential diagnostic and prognostic biomarker in SCLC clinical management.

Citations

Citations to this article as recorded by

Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer
Li Huang, Lei Han, Shuai Liang, Guohui Han
Cell Biology and Toxicology.2025;[Epub] CrossRef
Mechanistic insights on the role of competing endogenous RNA regulatory networks (ceRNETs) in small cell lung cancer
Sachin Kumar
Advances in Cancer Biology - Metastasis.2024; 10: 100117. CrossRef
A review on the role of KCNQ1OT1 lncRNA in human disorders
Mohammad Taheri, Zeinab Shirvani-Farsani, Atefeh Harsij, Mohadeseh Fathi, Sheyda Khalilian, Soudeh Ghafouri-Fard, Aria Baniahmad
Pathology - Research and Practice.2024; 255: 155188. CrossRef
Hydroquinidine Demonstrates Remarkable Antineoplastic Effects on Non-small Cell Lung Cancer Cells
Mervenur Yavuz, Turan Demircan
Current Molecular Medicine.2024; 24(9): 1159. CrossRef
Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Shuxin Li, Jianyi Lv, Zhihui Li, Qiuyu Zhang, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Changlong Li, Jinghui Wang, Hanping Shi, Li Deng, Zhenwen Chen, Xiaoyan Du
Molecular Cancer.2024;[Epub] CrossRef
A review of the complex interplay between chemoresistance and lncRNAs in lung cancer
Ghaliah Obaid Alnefaie
Journal of Translational Medicine.2024;[Epub] CrossRef
Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications
Ying Liu, Wei Ding, Jianxun Wang, Xiang Ao, Junqiang Xue
Frontiers in Oncology.2023;[Epub] CrossRef
Biological role of long non-coding RNA KCNQ1OT1 in cancer progression
Kai Zhan, Huafeng Pan, Zhang Zhou, Wenqian Tang, Zhining Ye, Shaogang Huang, Lei Luo
Biomedicine & Pharmacotherapy.2023; 169: 115876. CrossRef
Non-coding genome in small cell lung cancer between theoretical view and clinical applications
Xiaomeng Yin, Jiqiao Yang, Hang Wang, Yuling Luo, Zeyi Qin, Lei Deng, Xuelei Ma
Seminars in Cancer Biology.2022; 86: 237. CrossRef
KCNQ1OT1: An Oncogenic Long Noncoding RNA
Patrice Cagle, Qi Qi, Suryakant Niture, Deepak Kumar
Biomolecules.2021; 11(11): 1602. CrossRef

7,566 View
173 Download
10 Web of Science
10 Crossref

First
Prev
Page of 1
Next
Last

Search